INS and coronary artery disorder: The patient was on insulin Degludec (Tresiba®, Novo Nordisk A/S, Bagsværd, Denmark) and experienced two minor low-glucose events but no major complications; a 69-year-old male patient with diabetes, hypertension, and coronary artery disease who had a TIR of 56% on Tresiba® and oral medications, with an average glucose of 177 mg/dL and estimated HbA1c 7.5%, controlled glucose variability, and no hypoglycemic events.